Terlipressin Infusion for Management of Post-CABG Refractory Hypotension: A Comparative Study versus Nor-epinephrine Infusio
Not Applicable
Recruiting
- Conditions
- Circulatory SystemRespiratorySurgeryrefractory hypotension after cardiopulmonary bypass in diabetic patients
- Registration Number
- PACTR201705002221230
- Lead Sponsor
- Ahmed Mostafa El-Shaarawy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Diabetic patients
Undergoing elective CABG surgery using CPB
Normal ventricular function
Experience refractory hypotension after CPB
Exclusion Criteria
Emergency cardiopulmonary bypass
Pripheral vascular disease
Hepatic or Kidney dysfunction
preoperative unstable conditions such as severe arrhythmia, heart failure or cardiogenic shock
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie terlipressin's vasopressor effects in post-CABG refractory hypotension?
How does terlipressin compare to nor-epinephrine in managing postoperative hypotension in diabetic patients?
Are there specific biomarkers that predict response to terlipressin in post-CABG refractory hypotension?
What are the known adverse events associated with terlipressin use in post-CABG diabetic patients?
What combination therapies or alternative drugs show promise for treating post-CABG refractory hypotension in diabetics?